Celldex Therapeutics, Inc. (CLDX)
Q2 2012 Earnings Call
August 10, 2012, 08:30 am ET
Anthony Marucci - President & CEO
Chip Catlin - SVP & CFO
Tom Davis - SVP & Chief Medical Officer
Tibor Keler - SVP & Chief Scientific Officer
Jonathan Aschoff - Brean Murray
Mara Goldstein - Cantor Fitzgerald
Biren Amin - Jefferies
Joe Pantginis - Roth Capital Partners
Mani Mohindru - ThinkEquity
Steve Brozak - WBB Securities
Good morning and welcome to Celldex Therapeutics second quarter and 2012 update conference call. My name is Chanel and I will be your operator on today's call.
Before we begin our discussion, I have been asked to caution listeners that today's speakers will be making forward-looking statements. Such statements reflect current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements.
Certain of the factors that might cause Celldex’s actual results to differ materially from those in the forward-looking statements include those set forth under the heading Risk Factors and management’s discussion and analysis of financial condition and results of operations and Celldex’s annual report on Form 10-K quarterly reports on Form 10-Q and its current report on Form 8-K as well as those described in Celldex’s press release and filings with the Securities and Exchange Commission.
All forward-looking statements are expressly qualified in the entirety by this cautionary notice. You should carefully review all these factors and be aware that there maybe other factors that could cause these differences. These forward-looking statements are based on information, plans and estimates as of this call and Celldex does not promise to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other things.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts